Wells Fargo & Company Graphite Bio, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.24 - $2.66 $3,814 - $4,529	1,703 Added 22.92%	9,133 $23,000
Q3 2023 Nov 13, 2023	SELL	$2.18 - $2.77 $13,969 - $17,750	-6,408 Reduced 46.31%	7,430 $18,000
Q2 2023 Aug 15, 2023	BUY	$2.47 - $3.38 $25,890 - $35,429	10,482 Added 312.34%	13,838 $35,000
Q1 2023 May 12, 2023	BUY	$1.85 - $3.21 $5 - $9	3 Added 0.09%	3,356 $8,000
Q4 2022 Feb 13, 2023	SELL	$2.82 - $3.59 $549 - $700	-195 Reduced 5.5%	3,353 $11,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $236 - $356	84 Added 2.42%	3,548 $12,000
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $14,408 - $35,213	-6,733 Reduced 66.03%	3,464 $9,000
Q1 2022 May 16, 2022	SELL	$5.1 - $13.06 $13,846 - $35,457	-2,715 Reduced 21.03%	10,197 $52,000
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $83,763 - $166,431	9,960 Added 337.4%	12,912 $160,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $46,671 - $83,807	2,952 New	2,952 $48,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.